Our portfolio

We're accelerating ground-breaking discoveries into life-improving treatments through our robust and sustainable pipeline. Our therapeutic portfolio spans the entire drug discovery process, from early stage discovery through to first-in-human studies and beyond.

We've built an incredible assembly line for start-up companies to bring early-stage technologies out of the research lab and translate them into patient benefit.

To date, we've played a role in the creation of 79 start-ups, with our portfolio of existing companies raising in excess of £3bn in total capital.

CancerTools is a non-profit, global research tools collaborative where cancer researchers from over 180 institutes worldwide, contribute research tools and share knowledge to accelerate cancer research discoveries. 

We're helping to unlock the potential of this data by supporting researchers to improve the utility and accessibility of data, and establish secure, trusted, patient-approved data partnerships. 

Discover our oncology-focused data projects available for licensing or collaboration.

We're excited to launch our new quarterly newsletter, created to keep our biotech, pharma and investor communities informed at the forefront of translational cancer research.

Each edition will feature expert insights on emerging trends, alongside the latest news from across our work in drug discovery, clinical trials, licensing, partnerships and investment. You’ll also get exclusive content and thought leadership from the people shaping the future of oncology innovation.